Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is dated November 13, 2023. The report addresses the Company's efforts to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. The Company previously reported a stockholders' deficit of $1,760,000 in its 2022 Annual Report.
Key Financial Metrics and Debt
- Stockholders' Equity: Previously reported as a deficit of $1,760,000 (as of December 31, 2022). The filing indicates an expectation of regaining compliance through accounting adjustments and debt restructuring.
- Long-Term Debt Liability (NPV): As of September 30, 2023, the Net Present Value (NPV) of the liability from the European Investment Bank (EIB) decreased from $24.3 million to $18.6 million.
- Weighted Average Cost of Capital (WACC): Updated to 35% following an external appraisal post-September 30, 2023. This higher rate is expected to further lower the NPV of long-term liabilities.
- Functional Currency: Changed from NIS to USD to align with the new business strategy, impacting the classification of warrants from liabilities to equity.
Material Changes Versus Prior Period
The filing details significant changes in financial reporting and debt structure compared to prior periods:
- Debt Restructuring: The EIB approved an extension of the financial contract maturity date from December 31, 2027, to December 31, 2031. This four-year extension is expected to significantly lower the loan's NPV and improve shareholders' equity.
- Accounting Adjustments: The NPV of the EIB liability was recalculated based on a revised business strategy focusing on psoriasis and immunology therapeutics rather than accelerated COVID-19 development. Additionally, the change in functional currency reclassified most warrants as equity rather than liabilities.
- Strategic Pivot: The Company shifted focus from emergency drug development timelines to industry-standard timelines for biologics and the offering of CDMO services.
Outlook, Management Commentary, and Risks
Management believes the Company has regained compliance with the stockholders' equity requirement based on the EIB's approval of the new strategy and the resulting reduction in debt NPV. The EIB confirmed the extension is not due to a troubled loan situation or default, but rather reflects a strategic alignment for innovative young companies.
Risks and Contingencies:
- Compliance is contingent upon the formal documentation of the amendment to the Financial Contract with the EIB.
- Nasdaq will continue to monitor ongoing compliance. If the Company fails to evidence compliance in its next periodic report, it may be subject to delisting.
Key Facts for Investor Verification
- Confirmation that the formal amendment document extending the EIB loan maturity to 2031 has been signed.
- Verification of the updated stockholders' equity position in the next periodic financial report to confirm Nasdaq compliance.
- Impact of the 35% WACC and functional currency change on the full-year 2023 financial statements.
- Progress on the revised business strategy regarding psoriasis therapeutics and CDMO services.